title: Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age.
abstract: BACKGROUND
  The clinical manifestations and risk factors for developing coronary artery abnormalities (CAA) in Kawasaki disease (KD) might differ depending on age.
  
  
  METHODS
  From January 2001 to July 2007, 161 patients with an age younger than 1 year (younger group) and 60 patients with an age older than 5 years (older group) were diagnosed with KD at the Korea University Medical Center. Their medical records were reviewed retrospectively and the two groups were compared in terms of a number of variables commonly associated with the development of CAA, including clinical manifestations and laboratory findings.
  
  
  RESULTS
  While the overall incidence of KD-associated CAA in our hospital was 6.7%, CAA developed in 20 (12.4%) of the younger group and ten (16.7%) of the older group, respectively. The CAA (+) cases of the younger group had a longer duration of total fever (9.1 +/- 3.3 vs 6.3 +/- 1.9 days, p = 0.002) and showed fewer diagnostic symptoms (3.0 +/- 1.2 vs 4.3 +/- 1.1, p < 0.001) than the CAA (-) cases. The CAA (+) cases of the older group had a longer duration of total fever (14.1 +/- 10.4 vs 6.5 +/- 1.9 days, p = 0.045), especially with respect to post-intravenous gamma globulin (IVGG) fever (7.9 +/- 9.6 vs 1.1 +/- 0.8 days, p = 0.052), and had higher total white blood cell counts, erythrocyte sedimentation rates, C-reactive protein levels, total bilirubin levels, and Harada scores and lower serum albumin and sodium levels than the CAA (-) cases. Multivariable logistic regression analysis revealed that the factors that were associated significantly with the development of CAA were the number of total symptoms (OR = 0.494, 95% confidence interval (CI) = 0.281-0.871, p = 0.015) in the younger group and the duration of post-IVGG fever (OR = 1.958, 95% CI = 1.098-3.492, p = 0.023) and the Harada score (OR = 3.455, 95% CI = 1.012-11.796, p = 0.048) in the older group.
  
  
  CONCLUSIONS
  Incomplete clinical manifestations in the younger group and IVGG nonresponsiveness in the older group are associated with the development of KD-associated CAA. These age-specific characteristics could aid the customization of the diagnostic and therapeutic strategies of KD, thereby helping to improve the outcome of this disease.
authors.affiliation: Department of Pediatrics, Korea University College of Medicine, Seoul, South Korea.
authors.forename: DooIl
authors.initials: D
authors.lastname: Song
authors.forename: Yunku
authors.initials: Y
authors.lastname: Yeo
authors.forename: KeeSoo
authors.initials: K
authors.lastname: Ha
authors.forename: GiYoung
authors.initials: G
authors.lastname: Jang
authors.forename: JungHwa
authors.initials: J
authors.lastname: Lee
authors.forename: KwangChul
authors.initials: K
authors.lastname: Lee
authors.forename: ChangSung
authors.initials: C
authors.lastname: Son
authors.forename: JooWon
authors.initials: J
authors.lastname: Lee
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D002675:Child, Preschool; D003323:Coronary Aneurysm / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D003327:Coronary Disease / Q000150:complications; D003937:Diagnosis, Differential; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D015994:Incidence; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D045283:Natriuretic Agents / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011237:Predictive Value of Tests; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D007155:Immunologic Factors; D045283:Natriuretic Agents; D005719:gamma-Globulins; D020097:Natriuretic Peptide, Brain; D002097:C-Reactive Protein